Cutting-edge Research to be Presented at 7th Annual International Symposium on Mesothelioma at UCLA

LOS ANGELES, CA, UNITED STATES, August 24, 2017 / — On September 30th global experts on malignant pleural mesothelioma will again convene at the Meyer & Renee Luskin Conference Center at UCLA for the 7th Annual International Symposium on Malignant Pleural Mesothelioma (MPM), a rare form of cancer that results from exposure to asbestos and commonly affects the lining of the chest– the pleura. The event is jointly hosted by UCLA and the Pacific Mesothelioma Center (PMC).

The Symposium is geared towards physicians and offers continuing medical education (CME) credit. It will also provide up-to-date information on mesothelioma for medical students, nurses and other healthcare professionals, as well as mesothelioma patients, their families and other interested parties. Topics will cover: Surgery for Mesothelioma; Immune Checkpoint Blockades; Combining Angiogenesis Inhibition with Chemotherapy; Disabling Mitochondrial Peroxide Metabolism as an Effective Therapeutic Approach; Targeting the Epigenome in MPM; Recent Findings on Mesothelioma and BAP1 and more.

The Symposium will be led by Robert B. Cameron, MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center. The roster of distinguished international faculty at the Symposium will include Anna Nowak, PhD of the University of Western Australia; Luana Calabrò, MD, University Hospital of Sienna, Italy; David S. Schrump, MD, National Cancer Institute, Maryland; Jacques P. Fontaine, MD, Moffit Cancer Center, Tampa; Brian Cunniff, PhD, University of Vermont; Haining Yang, MD, PhD, University of Hawaii; Arti Shukla, PhD, University of Vermont as well as local experts from UCLA.

“This event highlights the most promising medical advances in the treatment of mesothelioma as well as promising new research,” said Dr. Cameron. “Over the past five years we’ve seen unprecedented advances in mesothelioma research that we never would have predicted a decade ago. Our intensive collaborations between laboratory and clinical scientists are yielding new insights into promising future treatments for mesothelioma such as immunotherapy, which is the most recent breakthrough for treating cancer. The symposium gives an unrivaled opportunity for both the medically savvy and general public, including mesothelioma patients, to not only learn first-hand about groundbreaking discoveries, but also to exchange ideas.”

The Symposium is supported by: Worthington & Caron, P.C., Waters, Kraus & Paul, and the International Association of Heat & Frost Insulators.

Early Bird tickets can be purchased before September 6th online at